Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN4A | P35499 | 3/20 | 0.47 |
| ▸ | SCN5A | Q14524 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | SCN1A | P35498 | 2/20 | 0.47 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.47 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.47 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.47 |
| ▸ | GBA1 | P04062 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1734411 | 1.00 | SCN4A (0.47) | SCN4ASCN5ALMNASCN1ASCN9A | |
| SCHEMBL1735307 | 1.00 | SCN4A (0.47) | SCN4ASCN5ALMNASCN1ASCN9A | |
| Hydrochloric Acid SCHEMBL9122119 | 0.98 | SCN5A (0.48) | SCN4ASCN5ALMNASCN1ASCN9A | |
| SCHEMBL9325826 | 0.88 | TACR1 (0.43) | SCN4ASCN5ALMNASCN1ASCN9A | |
| SCHEMBL13343217 | 0.87 | SCN4A (0.44) | SCN4ASCN5ALMNASCN1ASCN9A | |
| SCHEMBL22379972 | 0.86 | SCN4A (0.48) | SCN4ASCN5ALMNASCN1ASCN9A | |
| Trifluoroacetic Acid SCHEMBL29579653 | 0.83 | SCN9A (0.40) | SCN9AKMT2A | |
| Trifluoroacetic Acid SCHEMBL28646884 | 0.83 | SCN9A (0.40) | SCN9AKMT2A | |
| SCHEMBL18295355 | 0.80 | ADRB2 (0.56) | SCN4ASCN5ALMNASCN1ASCN9A | |
| SCHEMBL9124730 | 0.80 | ADRB2 (0.56) | SCN4ASCN5ALMNASCN1ASCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4208254-A | — | — | None | — | — | JP | disclosed |
| JP-4300857-A | — | — | None | — | — | JP | disclosed |
| JP-4334355-A | — | — | None | — | — | JP | disclosed |
| JP-4334355-A | — | — | None | — | — | JP | disclosed |
| JP-4300857-A | — | — | None | — | — | JP | disclosed |
| US-20190270696-A1 | COMPOUNDS AS INHIBITORS OF SODIUM CHANNELS | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2019-09-05 | — | — | US | disclosed |
| US-8759584-B2 | Synthesis of biguanidines and triazines, and biguanidino-aluminium complexes as intermediates | BAYER CROPSCIENCE AG (DE) | 2014-06-24 | — | — | US | disclosed |
| EP-2231679-B1 | SYNTHESIS OF BIGUANIDINES AND TRIAZINES, AND BIGUANIDINO-ALUMINIUM COMPLEXES AS INTERMEDIATES | BAYER CROPSCIENCE AG (DE) | 2011-11-16 | — | — | EP | disclosed |
| US-20100305317-A1 | SYNTHESIS OF BIGUANIDINES AND TRIAZINES, AND BIGUANIDINO-ALUMINIUM COMPLEXES AS INTERMEDIATES | BAYER CROPSCIENCE AG (DE) | 2010-12-02 | — | — | US | disclosed |
| US-20100113513-A1 | QUINOLINE DERIVATIVES AS FUNGICIDES | SYNGENTA CROP PROTECTION, INC. (US) | 2010-05-06 | — | — | US | disclosed |
| US-5420352-A | Reaction of alcohol with ammonia to form amine in a solvent in the presence of copper chromium catalyst and hydrogen | IDEMITSU KOSAN CO., LTD. (JP) | 1995-05-30 | — | — | US | disclosed |
| EP-0492615-B1 | Process for producing biguanide derivative | IDEMITSU KOSAN CO (JP) | 1995-03-08 | — | — | EP | disclosed |
| EP-0619294-A1 | PROCESS FOR PRODUCING 1-PHENOXY-2-AMINOPROPANE | IDEMITSU KOSAN COMPANY LIMITED (JP) | 1994-10-12 | — | — | EP | disclosed |
| US-5286905-A | Heating hydrogen halide salt of phenoxyalkylamine with dicyandiamide in paraffinic hydrocarbon solvent | IDEMITSU KOSAN COMPANY LIMITED (JP) | 1994-02-15 | — | — | US | disclosed |
| JP-H04334355-A | PRODUCTION OF 1-(3,5-DIMETHYLPHENOXY)-2-AMINOPROPANE | IDEMITSU KOSAN CO LTD | 1992-11-20 | — | — | JP | disclosed |
| JP-H04334355-A | PRODUCTION OF 1-(3,5-DIMETHYLPHENOXY)-2-AMINOPROPANE | IDEMITSU KOSAN CO LTD | 1992-11-20 | — | — | JP | disclosed |
| JP-H04300857-A | PRODUCTION OF 1-(3,5-DIMETHYLPHENOXY)-2-AMINOPROPANE | IDEMITSU KOSAN CO LTD | 1992-10-23 | — | — | JP | disclosed |
| JP-H04300857-A | PRODUCTION OF 1-(3,5-DIMETHYLPHENOXY)-2-AMINOPROPANE | IDEMITSU KOSAN CO LTD | 1992-10-23 | — | — | JP | disclosed |
| JP-H04208254-A | PRODUCTION OF PHENOXYALKYLAMINE DERIVATIVE | IDEMITSU KOSAN CO LTD | 1992-07-29 | — | — | JP | disclosed |
| EP-0492615-A1 | Process for producing biguanide derivative | IDEMITSU KOSAN COMPANY LIMITED (JP) | 1992-07-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113513-A1 | QUINOLINE DERIVATIVES AS FUNGICIDES | CYP1A1, CYP4X1, CYP3A7 | SCN4A 725/4885SCN5A 562/4885LMNA 4157/4885 |
| US-20190270696-A1 | COMPOUNDS AS INHIBITORS OF SODIUM CHANNELS | SCN1B, CACNA1E, SCN2B | SCN4A 48/4885SCN5A 34/4885LMNA 1789/4885 |
| US-20100305317-A1 | SYNTHESIS OF BIGUANIDINES AND TRIAZINES, AND BIGUANIDINO-ALUMINIUM COMPLEXES AS INTERMEDIATES | ATIC, SRM, F12 | SCN4A 693/4885SCN5A 109/4885LMNA 1744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.